Business
-
Invion Limited, which is developing several inhaled drugs, has announced a private placement in which it is issuing 71.5 million ordinary shares at $0.014 per share to “a US institutional investor” for a total of… Read more . . .
-
Aegis Therapeutics has announced that it received its first Russian patent (No. 2554814), titled, “Compositions for drug administration.” The patent covers formulations of triptans for the treatment of migraine that use Aegis’ Intravail transmucosal absorption… Read more . . .
-
Israeli biopharmaceutical company Advanced Inhalation Therapies (AIT), which recently received orphan drug status in Europe for its inhaled nitric oxide for the treatment of cystic fibrosis, has filed with the US Securities and Exchange Commission… Read more . . .
-
Skyepharma has reported that in-market sales of the flutiform fluticasone/formoterol MDI for the first 6 months of 2015 have totaled €65.1 million, up from €28.4 million in the first half of 2014, and the directors… Read more . . .
-
Raptor Pharmaceutical Co. plans to launch Quinsair inhaled levofloxacin inhalation solution in Europe and Canada by mid-2016, the company said after announcing that it has agreed to pay Tripex Pharmaceuticals $68.4 million upfront and up… Read more . . .
-
MannKind Corporation has announced the appointment of former Mylan CMO Raymond Urbanski as its Chief Medical Officer. Urbanski has also held positions at Metabolix, Pfizer, and Suntory, with experience in drug development for oncology, rheumatology,… Read more . . .
-
According to an update from Pulmatrix, the company has enough capital to fund development of its inhaled drug portfolio through the middle of 2017, and its plans over the next year and a half include… Read more . . .
-
Novartis Healthcare Private Limited has announced the launch of the Sequadra indacaterol/glycopyrronium (110mcg/50mcg) DPI for the treatment of COPD in India. Novartis’s indacaterol/glycopyrronium DPI is marketed in Europe and Japan as Ultibro Breezhaler. Novartis filed… Read more . . .
-
Cipla has announced that it will launch the Synchrobreathe breath-actuated inhaler, which the company says requires low inspiratory flow to actuate, by the end of 2015. Company executives discussed the new inhaler at the 2015… Read more . . .
-
Turing Pharmaceuticals, which is developing intranasal oxytocin for several indications has announced the completion of $90 million Series A financing round led by its Founder and CEO, Martin Shkreli. According to Turing, “the financing included… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden